Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine2020Vol. 383(19), pp. 1827–1837
Citations Over TimeTop 1% of 2020 papers
Jason D. Goldman, David Chien Lye, David S.C. Hui, Kristen Marks, Raffaele Bruno, Rocío Montejano, Christoph D. Spinner, Massimo Galli, Mi-Young Ahn, Ronald Nahass, Yao-Shen Chen, Devi SenGupta, Robert H. Hyland, Anu Osinusi, Huyen Cao, Christiana Blair, Xuelian Wei, Anuj Gaggar, Diana M. Brainard, William Towner, José Muñóz, Kathleen M. Mullane, Francisco M. Marty, Karen T. Tashima, George Diaz, Aruna Subramanian
Abstract
In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).
Related Papers
- → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)